Clavis Pharma to present at the 9th Annual Biotech in Europe Investor
Forum
(Thomson Reuters ONE) - Clavis Pharma ASA (OSE: CLAVIS) has been invited to present at the9th Annual Biotech in Europe Investor Forum, Zürich, on Monday 14September, 2009.Geir Christian Melen, CEO, will present the company from 2:30 PM atthe SIX Swiss Exchange, Zürich, Switzerland.The presentation will be made available on the Clavis Pharma websiteat www.clavispharma.com.Geir Christian Melen will be available for one-on-one meetings duringthe conference, which runs from 14-15 September 2009.For further information or booking of one-on-one meetings, pleasecontact:Geir Christian Melen, CEOOffice : +47 24 11 09 65Mobile : +47 91 30 29 65E-mail : geir.christian.melen(at)clavispharma.comGunnar Manum, CFOOffice : +47 24 11 09 71Mobile : +47 95 17 91 90E-mail : gunnar.manum(at)clavispharma.comFor international press enquiries:Mark Swallow / Nina Enegren / David DibleCitigate Dewe RogersonOffice : +44 207 282 2948E-mail : clavispharma(at)citigatedr.co.ukAbout Clavis PharmaClavis Pharma ASA is an oncology focused pharmaceutical company usingits proprietary Lipid Vector Technology (LVT) platform to create NewChemical Entities (NCEs), by significantly improving alreadyestablished drugs. The improvements are achieved by chemicallybinding specific unsaturated lipids to existing, and well understood,approved pharmaceuticals. Data generated suggests the resultingpatentable NCEs offer improved efficacy and reduced side effectsthrough enhanced pharmacokinetic properties, greater tissuepenetration and, in many cases, additional modes of action.Clavis Pharma's objective is to develop its drug candidates untilsignificant value has been created and proof of principle in man hasbeen shown. For further clinical development and commercialisation ofthe products, Clavis Pharma will enter into strategic partnershipswith established pharmaceutical or biotech companies. The company'sproduct portfolio includes four new cancer drugs: Elacytarabine is inClinical Phase II, Intravenous CP-4126 is in Clinical Phase II, OralCP-4126 in Phase I, and CP-4200 is in preclinical development.Results indicate that these products have promising potential forseveral cancer indications within solid tumours and leukaemia.The shares of Clavis Pharma ASA are listed on the Oslo Stock Exchange(ticker: CLAVIS).Additional information on Clavis Pharma can be found at:http://www.clavispharma.com/.This announcement was originally distributed by Hugin. The issuer is solely responsible for the content of this announcement.
Datum: 14.09.2009 - 10:00 Uhr
Sprache: Deutsch
News-ID 5770
Anzahl Zeichen: 0
contact information:
Town:
London
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 245 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Clavis Pharma to present at the 9th Annual Biotech in Europe Investor
Forum"
steht unter der journalistisch-redaktionellen Verantwortung von
Clavis Pharma ASA (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
